$109 million to fund Brain-Heart Interconnectome project to study brain-heart disorders

The CHEO Research Institute and the Lochmüller research group are excited to participate in a new uOttawa-led initiative funded by the Canada First Research Excellence Fund (CFREF) to establish a first-of-its-kind multidisciplinary program dedicated to the research of brain-heart conditions. This unique new project will lead a paradigm shift in the study, prevention, diagnosis and treatment of these conditions that will benefit patients in Canada and around the world.

The $109 million grant from CFREF will connect researchers from across uOttawa and affiliated research institutes with investigators from McGill University and the University of Saskatchewan to establish the Brain-Heart Interconnectome (BHI).

The Lochmüller Lab’s Role in the BHI

The BHI will be co-led by Dr. Peter Liu of the University of Ottawa Heart Institute and Dr. Ruth Slack of the University of Ottawa Brain and Mind Research Institute together with eight other principal investigators. As a principal investigator, Dr. Lochmüller will co-lead both the fundamental discovery and translational interconnectome and the therapeutic development theme, and will help guide research to discover how brain-heart disorders occur and progress, examining the interaction of genetic, environmental, and other conditions. Many neuromuscular diseases affect the heart and brain as well as the skeletal muscle, and the Lochmüller group will focus on developing advanced preclinical models of disease to test novel interventions for conditions affecting all these systems.

“Brain, mind and heart disorders are a complex set of interlinked conditions that together represent a tremendous burden both economically and for patients seeking diagnosis and therapies for these conditions,” explains Dr.  Lochmüller. “Traditionally, brain and heart conditions have been seen as separate disciplines, leaving gaps in our understanding of the relationships that exist between these disorders. The Brain-Heart Interconnectome will allow us to leverage the knowledge of experts in multiple disciplines to better understand these complex relationships and ultimately provide more effective therapies for patients with these diseases.”

More Information on the Brain-Heart Interconnectome Project

Read the full press release from the University of Ottawa.

Visit the Brain-Heart Interconnectome web page.


Read next...

We are hiring a new clinical research coordinator!

Lochmüller Research Group Hiring Clinical Trial Coordinator

Due to recent funding success and expansion of our clinical trials team we have a need for a highly motivated Research Coordinator that will assist...
First participant screened in global CMS natural history study

The Ottawa Neuromuscular Centre screens first participant in the world for a multinational congenital myasthenic syndrome natural history study

The neuromuscular centre at The Ottawa Hospital is excited to announce that we are the first site globally to screen a participant for the multinational...
Copy of Lochmuller Lab - PhD opportunity (LLab)

Lochmüller Lab seeking PhD student

The Lochmüller Research Group are seeking a highly motivated PhD student to join our team at the Childrens Hospital of Eastern Ontario Research Institute (CHEO...
New Publication - Leading global expert in DMD and bone health Dr. Leanne Ward publishes systematic review and grading of evidence for biphosphonate therapy in glucocorticoid-treated patients with Duchenne Muscular Dystrophy in Neurology, with Dr. Hanns Lochmüller as a co-author.

New Publication: Bisphosphonates in Glucocorticoid-Treated Patients with Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence

Leading global expert in Duchenne Muscular Dystrophy (DMD) and bone health Dr. Leanne Ward publishes systematic review and grading of evidence for bisphosphonate therapy in...
text reding new clinical trial opportunities

New Clinical Trial Opportunities for Children and Adults in Ottawa

Our clinical research team is excited to share five new clinical trials activated across both pediatric and adult sites in Ottawa, CHEO and TOH. We...
Dr. Andreas Roos receiving award on WMS 2023 stage, with text reading Congratulaions Dr. Andreas Roos, WMS President's Prize for Emerging Myologist of the Year 2023.

Dr. Andreas Roos wins Emerging Myologist of the Year Prize at WMS 2023

We are excited to congratulate Dr. Andreas Roos on winning the World Muscle Society’s (WMS) President’s Prize for Emerging Myologist of the Year!   This award...